This page reprints a manufacturer label. Everything below in quotation marks is copied from INDICATIONS:, published by FDA and retrieved on 2026-09-16. Nothing has been added, reworded or left out of the sections shown. It is the manufacturer’s label, reproduced as published.
This page reprints the FDA label for INDICATIONS: by Creative Science, a dextromethorphan and guaifenesin product labelled for dogs and cats. The sections below are copied from that label without change, with the set id and the date it was retrieved from DailyMed.
The label
Product: INDICATIONS:. Manufacturer: Creative Science. FDA Structured Product Label set id 44c16497-3077-4d7b-85ad-d1df01de4130. Label effective 2026-01-06. Retrieved 2026-09-16 from the DailyMed animal label release, and readable on DailyMed.
Indications
Expectorant, antitussive, and cough suppressant for temporary relief of cough symptoms in dogs and cats.
Dosage and Administration
SMALL DOGS and CATS: ½ tablet; repeat in four hours. LARGE DOGS: 1 tablet every four hours. NOTE: Do not use for puppies or kittens under 3 months of age or dogs or cats less than 5 lbs. (2.3 Kg) body weight. TAKE TIME... OBSERVE LABEL DIRECTIONS ACTIVE INGREDIENTS: Guaifenesin..........................................100 mg Dextromethorphan Hydrobromide.....10 mg
FDA adverse event reports
The FDA Center for Veterinary Medicine publishes the adverse event reports it receives through openFDA. The counts below are the reports naming dextromethorphan and guaifenesin as an active ingredient for each species this label names, as returned on 2026-09-16, coded by the VeDDRA reaction term the reporter chose. Reactions are counted per report, so one report can appear under several terms.
These are counts, not rates. Reporting is voluntary, the number of animals treated is not known, and a widely used product accumulates reports for that reason alone. A report records that an event followed a dose; it does not establish that the product caused it. The counts say nothing about how one product compares with another.
Dogs: 42 reports
| VeDDRA reaction term | Reports |
|---|---|
| Cough | 10 |
| Nasal discharge | 7 |
| Lack of efficacy - NOS | 6 |
| Lethargy (see also Central nervous system depression in Neurological) | 6 |
| Vomiting | 6 |
| Diarrhoea | 5 |
| Other abnormal test result NOS | 5 |
| Pneumonia | 5 |
| Abnormal radiograph finding | 4 |
| Ataxia | 4 |
| Conjunctivitis | 4 |
| Death by euthanasia | 4 |
| Elevated alanine aminotransferase (ALT) | 4 |
| Elevated serum alkaline phosphatase (ALP) | 4 |
| Neutrophilia | 4 |
Outcome as recorded by the reporter: Outcome Unknown 19; Ongoing 10; Recovered/Normal 6; Euthanized 4; Died 3.
Queries: reports, reactions, outcomes. Dataset: openFDA Animal and Veterinary Adverse Event Reports.
Cats: 0 reports
openFDA returned no reports for this ingredient in cats on 2026-09-16.
Queries: reports, reactions, outcomes. Dataset: openFDA Animal and Veterinary Adverse Event Reports.
Sources
- INDICATIONS:FDA · retrieved 2026-09-16
“SMALL DOGS and CATS: ½ tablet; repeat in four hours.” (Dosage and Administration)
- openFDA Animal and Veterinary Adverse Event ReportsFDA · retrieved 2026-09-16
Related
From Glarda
The note drafted from the consult, with the reference you just read sitting beside it in the shape your record already expects.